Sentinel lymph node in malignant melanoma

Česká verzia

Authors: Eva Rovenská
Authors place of work: Klinika chirurgickej onkológie Slovenskej zdravotníckej univerzity a Národného onkologického ústavu Bratislava, Slovenská republika, prednosta prof. MUDr. Juraj Pechan, CSc.
Published in the journal: Vnitř Lék 2014; 60(5-6): 484-489
Category: Review

Summary

Melanoma is highly malignant tumor which arises through malignant transformation of melanocytes. Surgical treatment of primary cutaneous melanoma including radical excision and intervention in regional lymphatic drainage is irreplaceable. Sentinel node biopsy is a recognized method of defining the stage of disease. Performance of sentinel node biopsy in patients in clinical stage Ib and II may reveal clinically occult nodal disease and thereby help identify a group of patients with occult stage III disease who may thereafter undergo complete lymphadenectomy and systemic treatment. Sentinel node biopsy is beneficial in treatment of melanoma, but the therapeutic value of sentinel node biopsy is still not completely clear and remains disputable.

Key words:
melanoma – sentinel lymph node – sentinel node biopsy

Zdroje

1. Krajsová I. Melanom. Maxdorf: Praha 2006. ISBN 80–7345–096–8.

2. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-update 2012. Eur J Cancer 2012; 48(15): 2375–2390.

3. Mervic L. Prognostic factors in patients with localized primary cutaneous melanoma. Acta dermatovenerol Alp Panonica Adriat 2012; 21(2): 27–31.

4. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36): 6199–6206.

5. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635–3648.

6. Sekula-Gibbs SA, Shearer MA Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. Dermatol Surg 2011; 37(8): 1080–1088.

7. Wong SL, Balch CM, Hurley P et al. Sentinel lymph node biopsy for melanoma: American society of clinical oncology and society of surgical oncology joint clinical practice guideline. J Clin Oncol 2012; 30(23): 2912–2918.

8. Mocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma. Revisiting the role of primary tumor excision margins. Ann Surg 2011; 253(2): 238–243.

9. Anderson KC, Alsina M, Bensinger W. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013; 11(1): 11–17.

10. Grotz TE, Glorioso JM, Pockaj BA et al. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery 2013; 153(4): 535–541.

11. Benca J, Rovenská E, Karaba M. Chirurgická terapia malígneho melanómu. Onkológia 2013; 8(3): 156–158.

12. Grotz TE, Markovic SN, Erickson LA et al. Mayo clinic consensus recommendations for the depth of excision in primary cutaneous melanoma. Mayo Clin Proc 2011; 86(6): 522–528.

13. Olsen G. Removal of fascia – cause of more frequent metastases of malignant melanomas of the skin to regional lymph nodes? Cancer 1964; 17: 1159–1164.

14. Hlavatá Z. Čaká nás „nová éra” v malígnom melanóme? Onkológia 2011; 6(5): 282–285.

15. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 2012; 29(7): 699–706.

16. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999; 230(4): 453–463.

17. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127(4): 392–399.

18. Balch CM, Morton DL, Gershenwald JE et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009; 60(5): 872–875.

19. Šimša J et al. Sentinelová uzlina. Lymfadenektomie u solidních nádorů. Maxdorf: Praha 2010. ISBN 978–80–7345–213–1.

20. Fait V, Chrenko V, Gatěk J et al. Biopsie sentinelové uzliny u kožních nádorů. In: Neoral Č, Bohanes T et al. Biopsie sentinelové uzliny. Galén: Praha 2012. ISBN 978–80–7262–882–7.

21. Baldwin BT, Cherpelis BS, Sondak V et al. Sentinel lymph node biopsy in melanoma: facts and controversies. Clin Dermatol 2010; 28(3): 319–323.

22. Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part II. J Am Acad Dermatol 2010; 62(5): 737–748.

23. Gauwerky KJ, Kunte C, Geimer T et al. The outcome of patients with melanoma is not associated with the time point of lymphatic mapping with respect to excisional biopsy of the primary tumor. Dermatology 2010; 220(4): 355–362.

24. Karakousis CP, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma. Ann Surg Oncol 1999; 6(8): 785–789.

25. McCready DR, Ghazarian DM, Hershkop MS et al. Sentinel lymph-node biopsy after previous wide local excision for melanoma. Can J Surg 2001; 44(6): 432–434.

26. Chakera AH, Hansen LB, Lock-Andersen J et al. In-transit sentinel nodes must be found: implication from a 10-year follow-up study in melanoma. Melanoma Res 2008; 18(5): 359–364.

27. Ortín-Pérez J, Vidal-Sicart S, Doménech B et al. In-transit sentinel lymph nodes in malignant melanoma. What is their importance? Rev Esp Med Nucl 2008; 27(6): 424–429.

28. Lens M. Sentinel lymph node biopsy in melanoma patients. J Eur Acad Dermatol Venereol 2010; 24(9): 1005–1012.

29. Badgwell BD, Pierce C, Broadwater JR et al. Intraoperative sentinel lymph node analysis in melanoma. J Surg Oncol 2011; 103(1): 1–5.

30. Koopal SA, Tiebosch AT, Albertus Piers D et al. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer 2000; 89(8): 1720–1725.

31. Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol 2004; 31(3): 357–362.

32. Scolyer RA, Murali R, McCarthy SW et al. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008; 25(2): 100–111.

33. Scolyer RA, Murali R, Satzger I et al. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol 2008; 17(3): 165–174.

34. Bogenrieder T, van Dijk MR, Blokx WAM et al. No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. Histopathology 2011; 59(2): 318–326.

35. Cook MG, Green MA, Anderson B et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200(3): 314–319.

36. Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part I. J Am Acad Dermatol 2010; 62(5): 723–734.

37. Shivers S, Jakub J, Pendas S et al. Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther 2007; 7(11): 1665–1674.

38. Romanini A, Manca G, Pellegrino D et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol 2005; 16(11): 1832–1840.

39. Garbe C, Eigentler TK, Bauer J et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: review of the literature and recommendations for general practice. J Dtsch Dermatol Ges 2011; 9(9): 690–699.

40. Piris A, Mihm jr. MC, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011; 38(5): 394–400.

41. Johnson T, Sondak VK, Bichakjian CK et al. The role of sentinel lymph node biopsy for melanoma: Evidence assessment. J Am Acad Dermatol 2006; 54(1): 19–27.

42. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma ...and beyond. Ann Surg Oncol 2010; 17(6): 1475–1477.

43. Balch CM, Gershenwald JE, Soong SJ et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28(14): 2452–2459.